10-Q: Senseonics Q2 Revenue Soars, Liquidity Boosted

Senseonics Holdings, Inc. reports significant revenue growth and improved gross margins in Q2 2025, bolstered by recent capital raises that alleviate going concern doubts.

Summary

• Total revenue increased by 36.7% to $6.6 million for the three months ended June 30, 2025, compared to $4.9 million for the same period in 2024.
• Gross profit significantly improved to $3.1 million in Q2 2025 from $0.3 million in Q2 2024, with gross margin rising to 46.9% from 6.1%.
• Net loss decreased to $14.5 million in Q2 2025, an improvement of $5.8 million compared to a $20.3 million net loss in Q2 2024.
• For the six months ended June 30, 2025, total revenue grew to $12.9 million from $9.9 million in 2024, and net loss improved to $28.8 million from $39.2 million.
• The company successfully raised approximately $72.2 million in net proceeds from a public offering and a private placement with Abbott Laboratories in May 2025.
• As of June 30, 2025, unrestricted cash, cash equivalents, and marketable securities totaled $126.4 million, leading management to conclude that going concern doubt has been alleviated.
• Research and development expenses decreased by $3.1 million in Q2 2025 due to the completion of Eversense 365 system clinical trials and headcount reduction.
• Sales to Ascensia, a related party, accounted for 52% of total revenue in Q2 2025 and 61% for the six months ended June 30, 2025.
• The company initiated first-in-human testing for its next-generation Gemini product in July 2024, aiming for a 2-in-1 glucose monitoring system.
• A collaboration agreement was entered into with Sequel Med Tech in April 2025 to integrate Eversense 365 with Sequel's twiist automated insulin delivery system, expected to be available to consumers in Q4 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significant improvements in gross margin and net loss, coupled with successful capital raises that alleviated going concern doubts. Strategic product advancements and partnerships are positive. However, continued net losses, high reliance on a single commercial partner, and ongoing legal/regulatory risks temper the overall sentiment.

Positives

• Total revenue increased significantly by 36.7% in Q2 2025 and 30.2% in H1 2025 year-over-year, driven by US sales growth, consignment program, and Eversense 365 demand.
• Gross profit and gross margin saw substantial improvements, with Q2 2025 gross margin at 46.9% (up from 6.1%) and H1 2025 gross margin at 35.8% (up from 6.4%).
• Net loss decreased by $5.8 million in Q2 2025 and $10.4 million in H1 2025 year-over-year, indicating improved operational efficiency.
• Successful capital raises in May 2025 generated approximately $72.2 million in net proceeds, significantly strengthening the company's liquidity position.
• Management has concluded that the doubt about the company's ability to continue as a going concern has been alleviated.
• Research and development expenses decreased due to the completion of Eversense 365 clinical trials, indicating progress in product development cycles.
• Expansion of the Eon Care network and increased direct-to-consumer (DTC) spending are aimed at accelerating Eversense adoption.
• Medicare coverage was expanded for Eversense E3 and updated for Eversense 365, broadening patient access.
• New collaboration with Sequel Med Tech aims to create an innovative once-yearly CGM integrated with an automated insulin delivery system.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $976.6 million as of June 30, 2025.
• A significant portion of the company's revenue (52% in Q2 2025, 61% in H1 2025) is derived from a single customer, Ascensia, posing concentration risk.
• Selling, general and administrative expenses increased, primarily due to higher sales commissions to Ascensia and costs for Eon Care subsidiaries.
• Net cash used in investing activities increased substantially to $95.0 million in H1 2025, primarily due to purchases of marketable securities.
• The company's commercial success is heavily dependent on Ascensia's efforts, and there is ongoing assessment regarding Ascensia's spending against target requirements.

Risks

• The Commercialization Agreement with Ascensia may not be successful, potentially leading to failure to meet spending or revenue targets, or modification/termination of the agreement.
• Limited operating history as a commercial-stage company may lead to difficulties in competitive and rapidly evolving markets.
• Inability to successfully expand commercialization of Eversense in the United States and Europe through the collaboration with Ascensia.
• Dependence on third-party payor coverage and adequate reimbursement for Eversense and related procedures.
• Ongoing responsibilities under U.S. and EU regulations, with potential for adverse regulatory actions, inspections, or product restrictions.
• The collaboration agreement with Sequel Med Tech may not lead to anticipated benefits, facing risks such as cost overruns, distraction from other priorities, insufficient resources, technological challenges, intellectual property disputes, and regulatory compliance.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the company's global supply chain, increase costs, and reduce profitability.
• The company will need to generate significant sales to achieve profitable operations, which may not occur, leading to continued financial losses.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel in a competitive environment.
• Difficulties in managing growth, including expanding development, regulatory, marketing, and distribution capabilities, could disrupt operations.

Future Outlook

The company expects to incur additional losses in the near future but believes it has sufficient resources to meet anticipated operating needs over the next twelve months, alleviating prior going concern doubts. It plans to continue increasing investment in direct-to-consumer (DTC) spending into the third and fourth quarters of 2025 to drive Eversense adoption. The company anticipates that established CPT codes for Eversense insertions will enable a self-sustaining economic model for its Eon Care initiative. A CE Mark submission for Eversense 365 was made in Q1 2025, with a planned launch in European Union member countries in the second half of 2025 if approved. An Investigational Device Exemption (IDE) submission for the Gemini product is anticipated in the second half of 2025, and the integrated Eversense 365 and Sequel's twiist automated insulin delivery system is expected to be available to consumers in the fourth quarter of 2025.

Management Comments

• "Based on current operating plans, the receipt of financing proceeds, its existing unrestricted cash and cash equivalents, management now believes that the Company has sufficient resources to meet the Company’s anticipated operating needs over the next twelve months."
• "Accordingly, management has concluded that the doubt about the Company’s ability to continue as a going concern has been alleviated."
• "We are determined to increase investment in supporting DTC spending, which we believe correlates with higher awareness and adoption of Eversense. We expect this investment to continue into the third and fourth quarters."
• "Although the rate of Eversense adoption and lead generation has increased following these initiatives, as well as the regulatory approval of Eversense 365, we continue to work closely with Ascensia to accelerate commercialization and adoption of our product."
• "We regularly engage in discussions with Ascensia regarding the market opportunity for Eversense, the degree of our respective spending on commercialization, and the potential impact of greater commercial support on product uptake."
• "We continue to assess with Ascensia ways in which we can modify our plans and arrangements and expand or introduce new commercial activities to accelerate commercialization and product adoption."

Industry Context

Senseonics operates in the dynamic and competitive continuous glucose monitoring (CGM) market, distinguishing itself with long-term implantable systems like Eversense E3 (180-day) and Eversense 365 (365-day), which offer significantly longer wear times compared to typical 7-15 day non-implantable CGMs. The company's strategy relies heavily on strategic partnerships, notably with Ascensia for global commercialization and Abbott Laboratories for investment, and a new collaboration with Sequel Med Tech to develop an integrated automated insulin delivery system. This focus on extended wear and integrated solutions positions Senseonics to address unmet needs in diabetes management, particularly for patients seeking less frequent sensor changes and potentially more comprehensive glucose management solutions.

Comparison to Industry Standards

• Eversense E3 offers a 180-day sensor life, significantly longer than typical non-implantable CGM systems which last 7-15 days.
• Eversense 365 extends sensor life to 365 days with once-per-week calibration, further differentiating it from shorter-duration devices.
• The Eversense system is noted for its MRI compatibility, a unique feature as 'all other sensors are required to be removed during an MRI scan'.
• The collaboration with Sequel Med Tech aims to create the 'first ever automated insulin delivery system with a once-yearly CGM', setting a new benchmark for integrated diabetes care.

Legal Proceedings

• A civil complaint was filed by Cellspin Soft, Inc. against Senseonics Holdings, Inc. and Ascensia Diabetes Care Holdings AG (Case No. 2:24-cv 263) in the Eastern District of Texas, alleging patent infringement of three patents.
• The validity of these three patents is being challenged in Inter Partes Review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) by TikTok Inc. (TikTok IPR), with a review instituted on September 30, 2024.
• On October 30, 2024, Senseonics, LifeScan, Inc., and Ascensia filed a joint motion to join the TikTok IPR and their own independent, similar IPR challenges.
• On February 5, 2025, the court stayed the proceedings in the Eastern District of Texas pending resolution of the Inter Partes Reviews.
• On June 5, 2025, the Acting Director of the USPTO ordered a sua sponte review of whether the TikTok IPR could proceed based on novel issues related to TikTok's Chinese ownership status, staying the IPR proceedings.
• The company intends to vigorously defend the lawsuit should any asserted claim in the three patents survive the invalidity challenge in the Inter Partes Review proceedings.

Related Party Transactions

• Ascensia, a subsidiary of PHC Holdings Corporation (PHC), is a related party due to PHC's noncontrolling ownership interest and Board representation.
• Revenue from Ascensia was $7.9 million for the six months ended June 30, 2025, accounting for 61% of total revenue (down from 86% in H1 2024).
• Ascensia earned commissions of $2.6 million on sales made through the consignment channel during the six months ended June 30, 2025 (up from $0.2 million in H1 2024).
• Amount due from Ascensia was $2.3 million as of June 30, 2025 (down from $4.9 million as of December 31, 2024).
• Amount due to Ascensia was $2.6 million as of June 30, 2025 (up from $1.8 million as of December 31, 2024).
• The company purchased less than $0.1 million in medical supplies from Ascensia for clinical trials during both H1 2025 and H1 2024.
• Abbott Laboratories, a related party, participated in a private placement in May 2025, purchasing 40,539,265 shares of common stock for approximately $20.3 million.

Stakeholder Impact

• Shareholders: Experienced dilution from recent capital raises but benefited from improved liquidity, alleviated going concern risk, and potential future value from product commercialization and pipeline advancements.
• Employees: Saw a reduction in R&D headcount but an increase in personnel costs to support the expansion of Eon Care subsidiaries; future growth depends on attracting and retaining qualified personnel.
• Customers (Diabetes Patients & Healthcare Providers): Gained increased access to Eversense systems through expanded insurance coverage, the Eon Care network, and the introduction of longer-duration products like Eversense 365, with future innovations like Gemini and the Sequel collaboration promising enhanced diabetes management solutions.
• Suppliers: The company's reliance on third-party manufacturers and a global supply chain exposes them to potential impacts from international trade policies and tariffs.
• Creditors: The repayment of the 2025 Notes and compliance with the Loan and Security Agreement covenants indicate an improved financial position and reduced credit risk.

Next Steps

• Continue to increase investment in supporting Direct-to-Consumer (DTC) spending into the third and fourth quarters of 2025.
• Build out and establish the Eon Care network, expecting a self-sustaining economic model from CPT codes for Eversense insertions.
• Work closely with Ascensia to accelerate commercialization and adoption of Eversense, including assessing and modifying commercial plans and arrangements.
• Launch Eversense 365 with Ascensia in the second half of 2025, pending CE Mark approval.
• Utilize data from Gemini first-in-human testing for an Investigational Device Exemption (IDE) submission anticipated in the second half of 2025.
• Expect availability of the integrated Eversense 365 and Sequel's twiist automated insulin delivery system in the fourth quarter of 2025.
• Vigorously defend the patent infringement lawsuit if asserted claims survive the invalidity challenge in the Inter Partes Review proceedings.

Key Dates

Recommendation

The company has demonstrated significant operational improvements, including strong revenue growth and gross margin expansion, and has successfully addressed its near-term liquidity concerns by raising substantial capital. The alleviation of the going concern doubt is a major positive. Strategic partnerships and pipeline advancements (Eversense 365, Gemini, Sequel collaboration) offer future growth potential. However, the company remains unprofitable with a large accumulated deficit, and its commercial success is heavily reliant on Ascensia, which carries inherent risks. The ongoing patent litigation, though stayed, also presents a contingent liability. Given the progress but also the remaining challenges and dependencies, a 'Hold' recommendation is appropriate for a seasoned investor, suggesting monitoring for sustained profitability and successful execution of commercial and development strategies.

Keywords

Continuous Glucose Monitoring, CGM, Diabetes Management, Implantable Sensor, Eversense, Medical Device, Senseonics, Abbott Laboratories, Ascensia Diabetes Care, Sequel Med Tech, FDA Approval, CE Mark, Financial Results, Capital Raise, Biotechnology